In:
Ophthalmic Surgery, Lasers and Imaging Retina, SLACK, Inc., Vol. 47, No. 8 ( 2016-08), p. 716-723
Abstract:
To determine factors predicting response to ocriplasmin (Jetrea; ThromboGenics, Iselin, NJ) response in patients with symptomatic vitreomacular adhesion (VMA). PATIENTS AND METHODS: Combined analysis of two multicenter, prospective, randomized, double-masked trials of intravitreal ocriplasmin 125 µg injection versus placebo. Patients had vitreomacular traction with or without a full-thickness macular hole (FTMH). Multivariate logistic regression was used to determine factors influencing treatment response (complete VMA release [day 28] and non-surgical FTMH closure [month 6] ). RESULTS: Younger age, presence of FTMH (odds ratio [OR] = 2.1; 95% confidence interval [CI] , 1.1–3.7), VMA diameter of 1,500 µm or less (OR = 4.9; 95% CI, 2.0–12.4), phakic lens status (OR = 2.8; 95% CI, 1.5–5.2), and absence of epiretinal membrane (OR = 4.1; 95% CI, 2.2–7.9) predicted VMA resolution. FTMHs with apical diameter of 250 µm or less were more likely to close than larger holes (58.3% vs. 24.6%; P = .013). Both FTMH size groups had significantly greater chance of VMA resolution and FTMH closure versus controls. CONCLUSION: Ocriplasmin is most effective in younger patients with focal VMA and without an epiretinal membrane. [ Ophthalmic Surg Lasers Imaging Retina . 2016;47:716–723.]
Type of Medium:
Online Resource
ISSN:
2325-8160
,
2325-8179
DOI:
10.3928/23258160-20160808-04
Language:
English
Publisher:
SLACK, Inc.
Publication Date:
2016
Bookmarklink